Abstracts Archive - Page 272 of 2607 - ACR Meeting Abstracts

Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0655 • ACR Convergence 2024
Relationship Between Patient-Reported Outcomes to Hospitalization in Patients Living with SLE: A Retrospective Cohort Study Utilizing the FORWARD Lupus Registry
Minjee Park¹, Sofia Pedro², Jean-Francois Ricci¹, Kaleb Michaud³ and Patti Katz⁴, ¹Alira Health, Basel, Switzerland, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴UCSF, San Rafael, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with diverse symptoms and multisystemic manifestations. Reducing exacerbations (flares), often leading to hospitalization, remains a challenge…
Abstract Number: 0645 • ACR Convergence 2024
Mortality and Ethnicity in Adults with Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Analysis
Samir Patel¹, Zijing Yang¹, deepak Nagra¹, Maryam Adas², Mark Russell¹, Sam Norton¹, Chris Wincup³, James Galloway⁴, Kate Bramham² and Patrick Gordon⁵, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁵nhs, London, United Kingdom
Background/Purpose: Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. Systemic lupus erythematosus (SLE) is a disease with higher incidence in non-White populations…
Abstract Number: 0620 • ACR Convergence 2024
Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Benjamin A. Fisher¹, Hendrika Bootsma², Vibeke Strand³, Wan-Fai Ng⁴, Thomas Wegman⁵, Brandon Becker⁶, Jiyoon Choi⁶, Antoine Sreih⁶, Leo Chen⁷, Antonia Christodoulou⁶ and Eric Morand⁸, ¹University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, ⁵Bristol Myers Squibb, Beaver Falls, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Richmond, BC, Canada, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
Abstract Number: 0422 • ACR Convergence 2024
Greater Use of Assisted Reproductive Techniques but Comparable Obstetric Morbidity in a Population of Women with Spondyloarthritis: A Matched Comparative Analysis of the GR2 Prospective Cohort and the French National Perinatal Surveys
Sabrina Hamroun¹, Grégoire Martin De Frémont², Nathalie Costedoat-chalumeau³, Marion couderc⁴, René-Marc Flipo⁵, Jérémie Sellam⁶, Christophe Richez⁷, Rakiba Belkhir⁸, Laure Gossec⁹, Hubert Marotte¹⁰, Emmanuelle Dernis¹¹, Aline Frazier¹², Elisabeth Gervais¹³, Cedric Lukas¹⁴, Valerie Devauchelle¹⁵, Alban Deroux¹⁶, Véronique Le Guern¹⁷, Gaëlle Guettrot-Imbert¹⁸, Nathalie Lelong¹⁹, Camille Le Ray¹⁹, Raphaele Seror²⁰ and Anna Molto²¹, and ENP 2021 and GR2 Study Groups, ¹Cochin University Hospital, Paris, Ile-de-France, France, ²Le Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, Guyana, ³University Paris Cité, Paris, France, ⁴CHU de Clermont-Ferrand, Clermont-Ferrand, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France, ⁶Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France, ⁷Pellegrin Hospital, Rheumatology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Bordeaux, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France, ⁹Sorbonne Université, Paris, France, ¹⁰Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹¹CH LE MANS, LE MANS, Pays de la Loire, France, ¹²Lariboisière University Hospital, Paris, France, ¹³University hospital, Poitiers, France, ¹⁴Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁵UBO, Brest, France, ¹⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁷APHP, Hôpital Cochin, Paris, ¹⁸Cochin Hospital, Paris, France, ¹⁹University of Paris, INSERM Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France, ²⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²¹Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) regularly affects women of childbearing age1. A higher obstetric morbidity in women with SpA is suggested in the literature in several countries,…
Abstract Number: 0619 • ACR Convergence 2024
Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, BETTINA ESCOLANO², ENOCH J ABBEY² and Amanda Sammut³, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ³New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…
Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Nelly Ziade¹, Sherif Gamal², Maroun Aoun³, Ihsane Hmamouchi⁴, Clementina López Medina⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²Cairo University, Cairo, Egypt, ³Saint Joseph University, Beirut, Lebanon, ⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
Abstract Number: 0431 • ACR Convergence 2024
Reproductive Health in Women with Rheumatic Diseases: Knowledge and Behaviors
Abraham Yair Lujano-Negrete¹, Lorena Perez-Barbosa², Conrado Garcia³, CASSANDRA SKINNER TAYLOR⁴, Jose Hernandez Linas³, Adriana Lobato-Belmonte³, Yesenia Ambriz Murillo⁵, Alfonso Gastelum-Strozzi⁶, Amaranta Manrique de Lara⁷, Ana Rodriguez-Flores⁸, Jesus Cardenas-de la Garza⁹, Marco Maradiaga-Cecena¹⁰, Galilea Rodriguez Orozco¹¹, Anahí Carrazco Chapa¹¹, Dionicio Galarza-Delgado¹² and Ingris del Pilar Pelaez Ballestas³, and Grupo de estudio de salud reproductiva en enfermedades reumáticas autoinmunes en Mexico, ¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Internal Medicine, Monterrey, Mexico, Monterrey, Mexico, ²Hospital Universitario, UANL, Monterrey, Mexico, ³Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico, Mexico, ⁴HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁵Hospital Regional de Morelia, Rheumatology, Morelia, Mexico, Morelia, Mexico, ⁶Instituto de Ciencias Aplicadas y Tecnología, UNAM, Mexico City, Mexico, Monterrey, Mexico, ⁷Hospital General de Mexico Dr. Eduardo Liceaga, Rheumatology, Mexico City, Mexico, Mexico City, Mexico, ⁸Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ¹⁰Hospital General de Culiacan, Rheumatology, Culiacan, Mexico, Culiacan, Sinaloa, Mexico, ¹¹Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ¹²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) affect women during their childbearing years, often leading to pregnancy complications. Effective management of this population requires family planning and…
Abstract Number: 0639 • ACR Convergence 2024
Delayed Diagnosis in Systemic Lupus Erythematosus
Romina Nieto¹, Lucia Hernandez², Nidia Noemí Merás³, Bordón Florencia Juliana⁴, Cintia Otaduy⁵, Lucila Garcia⁶, Rosa Serrano Morales⁷, Nicolás Pérez⁸, Micaela A. Cosatti⁹, Ana Carolina Montandon¹⁰, Gustavo Flores Chapacais¹¹, Laissa C. Alves Alvino¹², Emily Figuereido Neves¹³, Eloisa Bonfa¹⁴, Alexis Bondi Peralta¹⁵, Loreto Massardo¹⁶, Andrés Cadena Bonfanti¹⁷, Andrés Hormaza¹⁸, José Martínez¹⁹, Olga Lidia Vera Lastra²⁰, Hilda Fragoso-Loyo²¹, ⁠Yaneli Juárez-Vicuña²², Diana Fernandez²³, Patricia Langjarth²⁴, Maria Teresa Martinez de Filartiga²⁵, Manuel Ugarte-Gil²⁶, Carlos Alejandro Loayza Flores²⁷, Teresandris Polanco²⁸, Maria Belen Lecumberri²⁹, Álvaro Danza³⁰, Carlos Enrique Toro-Gutierrez³¹, Urbano Sbarigia³², Ashley Orillion³³, Federico Zazzetti³⁴, Graciela Alarcon³⁵, Bernardo Pons-Estel² and Guillermo Pons-Estel³⁶, and Grupo Latino Americano de Estudio del Lupus (GLADEL), ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ³Hospital Italiano de Córdoba, Cordoba, Argentina, ⁴Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁵Hospital Córdoba, Cordoba, Spain, ⁶Servicio de Reumatología del HIGA San Martín, La Plata, Argentina, ⁷Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁸Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁹CEMIC Centro de Educación Médica e Investigaciones Clínicas ''Norberto Quirno'' CABA, CABA, Argentina, ¹⁰Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ¹¹Rheumatology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹³Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ¹⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ¹⁵Hospital del Salvador, Santiago, Chile, ¹⁶Centro de Biología Celular y Biomedicina CEBICEM, Facultad de Medicina y Ciencias Universidad San Sebastián, Santiago, Chile, ¹⁷Universidad Simon Bolivar, Barranquilla, Colombia, ¹⁸Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ¹⁹Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ²⁰División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²²Instituto Nacional de Cardiología Ignacio Chávez, Departamento de Inmunología, Investigador en Ciencias Médicas C, Mexico City, Mexico, ²³Member of GLADEL, Rosario, Argentina, ²⁴Hospital de Clínicas I, Asunción, Paraguay, ²⁵Dpto de Reumatología Hospital de Clínicas. Facultad de Ciencias medicas.Universidad Nacional de Asunción, Asuncion del Paraguay, Paraguay, ²⁶Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ²⁷Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ²⁸Hospital Docente Padre Billini, Santo Domingo, Dominica, ²⁹Hospital Señor del Milagro, Salta, Argentina, ³⁰Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, ³¹Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, ³²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³³Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ³⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ³⁵The University of Alabama at Birmingham, Oakland, CA, ³⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease of unknown etiology. Diagnosis is often delayed because it frequently mimics symptoms of other diseases;…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 0601 • ACR Convergence 2024
Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Peter C. Taylor¹, Lihi Eder², Yael Klionsky³, Fabian Proft⁴, Thomas Iyile⁵, Erin Mancl⁶, Priscila Magalhaes Reis Nakasato⁷, Xiaolan Ye⁸, Limei Zhou⁶ and Philip Mease⁹, ¹University of Oxford, Oxford, United Kingdom, ²University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵AbbVie Inc., hyattsville, MD, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., Randolph, NJ, ⁸AbbVie Inc., Mettawa, IL, ⁹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

Background/Purpose: Severe musculoskeletal manifestations of PsA, particularly joint pain, can result in reduced physical function, decreased quality of life, and progressive and irreversible joint damage.1,2…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0469 • ACR Convergence 2024
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Cristina Campos Fernández¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Pablo Martínez Calabuig⁴, Laura Salvador Maicas⁵, Mireia Lucía Sanmartín Martínez⁶, Iván Jesús Lorente Betanzos⁶, Clara Molina Almela⁶, juan José Lerma Garrido⁷, Amalia Rueda³ and Jose A Román-Ivorra⁸, ¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ²Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁴HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ⁵Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ⁶Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) escalates the risk of premature mortality, predominantly through cardiovascular diseases. Although SCORE and its updated version, SCORE2, are employed to assess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].